Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction, and many other devastating diseases. Our purpose to accelerate treatments and fundamentally improve mental health.

Gilgamesh is a serious mental health science-focused, a preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE’s) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions. Gilgamesh has a nuanced understanding of the world of psychedelic medicine which guides the creation of new chemical entities with a high probability for success.